JP2012528166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528166A5 JP2012528166A5 JP2012513170A JP2012513170A JP2012528166A5 JP 2012528166 A5 JP2012528166 A5 JP 2012528166A5 JP 2012513170 A JP2012513170 A JP 2012513170A JP 2012513170 A JP2012513170 A JP 2012513170A JP 2012528166 A5 JP2012528166 A5 JP 2012528166A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutically acceptable
- independently selected
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- -1 —NR a R b Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims 5
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- JXCVMJKEIAJDTR-PMACEKPBSA-N (2s)-n-[5-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]-1,2-benzoxazol-3-yl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C1=C2)=NOC1=CC=C2C(C=C1)=CC=C1C(N1)=CN=C1[C@@H]1CCCN1 JXCVMJKEIAJDTR-PMACEKPBSA-N 0.000 claims 1
- YFWSCHXAXPPKRF-SFTDATJTSA-N (2s)-n-[5-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]-1h-indazol-3-yl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C1=C2)=NNC1=CC=C2C(C=C1)=CC=C1C(N1)=CN=C1[C@@H]1CCCN1 YFWSCHXAXPPKRF-SFTDATJTSA-N 0.000 claims 1
- WBNAUPFGRVUWEN-PMACEKPBSA-N (2s)-n-[6-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]-1,2-benzoxazol-3-yl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C1=CC=2)=NOC1=CC=2C(C=C1)=CC=C1C(N1)=CN=C1[C@@H]1CCCN1 WBNAUPFGRVUWEN-PMACEKPBSA-N 0.000 claims 1
- WGDXYMATFCDOFZ-PMACEKPBSA-N (2s)-n-[6-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]-1h-indazol-3-yl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C1=CC=2)=NNC1=CC=2C(C=C1)=CC=C1C(N1)=CN=C1[C@@H]1CCCN1 WGDXYMATFCDOFZ-PMACEKPBSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- OPANAHUKQCTHKE-SVBPBHIXSA-N tert-butyl (2s)-2-[5-[4-[3-[[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]amino]-1,2-benzoxazol-6-yl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)NC1=NOC2=CC(C=3C=CC(=CC=3)C=3NC(=NC=3)[C@H]3N(CCC3)C(=O)OC(C)(C)C)=CC=C12 OPANAHUKQCTHKE-SVBPBHIXSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18216209P | 2009-05-29 | 2009-05-29 | |
| US61/182,162 | 2009-05-29 | ||
| PCT/US2010/036033 WO2010138488A1 (en) | 2009-05-29 | 2010-05-25 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528166A JP2012528166A (ja) | 2012-11-12 |
| JP2012528166A5 true JP2012528166A5 (cg-RX-API-DMAC7.html) | 2013-06-06 |
| JP5615352B2 JP5615352B2 (ja) | 2014-10-29 |
Family
ID=42990555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513170A Expired - Fee Related JP5615352B2 (ja) | 2009-05-29 | 2010-05-25 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8211928B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2435429B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5615352B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102459250B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010138488A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075380A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010120935A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| CN103819459B (zh) | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012008658A (es) | 2010-01-25 | 2012-12-05 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c. |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| EP2542074A4 (en) | 2010-03-04 | 2014-05-14 | Enanta Pharm Inc | PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104684910B (zh) * | 2012-07-12 | 2016-10-12 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| EP3650013A1 (en) | 2013-01-31 | 2020-05-13 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| SI3038601T1 (sl) | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN107428696B (zh) * | 2015-02-16 | 2021-08-20 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20200083532A (ko) | 2017-10-31 | 2020-07-08 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법 |
| EP4341266A1 (en) | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
| US12497408B2 (en) | 2021-05-21 | 2025-12-16 | Gilead Sciences, Inc. | Tetracyclic compounds and methods for the treatment of Zika virus infection |
| JP2025510989A (ja) * | 2022-03-30 | 2025-04-15 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としての置換された３－アミノインダゾール誘導体 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994015909A1 (en) | 1993-01-14 | 1994-07-21 | Magainin Pharmaceuticals, Inc. | Amino acids and peptides having modified terminals |
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| WO2004005264A2 (en) | 2002-07-05 | 2004-01-15 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| BRPI0612317B8 (pt) * | 2005-06-20 | 2021-05-25 | Janssen R & D Ireland | benzimidazóis 2-substituídos, seu processo de preparação e composição farmacêutica |
| DK1940786T3 (da) | 2005-09-16 | 2010-11-08 | Arrow Therapeutics Ltd | Biphenylderivater og deres anvendelse ved behandling af hepatitis C |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| JP2009521479A (ja) | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| CA2653924A1 (en) | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| CA2672267C (en) | 2006-07-27 | 2016-05-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100055071A1 (en) | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| MX2010008699A (es) | 2008-02-12 | 2010-08-30 | Bristol Myers Squibb Co | Derivados heterociclicos como inhibidores de virus de la hepatitis c. |
| BRPI0822335A2 (pt) | 2008-02-12 | 2019-09-24 | Bristol-Myers Squibb Company | inibidores do vírus da hepatite c |
| CN102007122B (zh) | 2008-02-13 | 2013-09-04 | 百时美施贵宝公司 | 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑 |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| CA2750577A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| EP2400846B1 (en) | 2009-02-27 | 2016-10-05 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| MY169311A (en) | 2009-03-27 | 2019-03-21 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010120935A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| RU2528231C2 (ru) | 2009-04-24 | 2014-09-10 | Тиботек Фармасьютикалз | Диариловые эфиры |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| AU2010253791A1 (en) | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103819459B (zh) | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| AU2010280711A1 (en) | 2009-08-07 | 2012-02-09 | Janssen Sciences Ireland Uc | Phenyl ethynyl derivatives as hepatitis C virus inhibitors |
| US8623899B2 (en) | 2009-08-07 | 2014-01-07 | Janssen Research & Development Ireland | Bis-benzimidazole derivatives as hepatitis C virus inhibitors |
| CN102482260A (zh) | 2009-09-03 | 2012-05-30 | 泰博特克药品公司 | 双-苯并咪唑衍生物 |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| TWI429645B (en) | 2009-12-04 | 2014-03-11 | Proline derivatives | |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ600608A (en) | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| MX2012008658A (es) | 2010-01-25 | 2012-12-05 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c. |
| JP2013518062A (ja) | 2010-01-28 | 2013-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
-
2010
- 2010-05-24 US US12/785,665 patent/US8211928B2/en active Active
- 2010-05-25 CN CN201080034457.4A patent/CN102459250B/zh not_active Expired - Fee Related
- 2010-05-25 WO PCT/US2010/036033 patent/WO2010138488A1/en not_active Ceased
- 2010-05-25 JP JP2012513170A patent/JP5615352B2/ja not_active Expired - Fee Related
- 2010-05-25 EP EP10720511.4A patent/EP2435429B1/en not_active Not-in-force